The legislation, SB 2385, filed by state Sen. David Koehler, D-Peoria, would curb PBM abuses by stopping steering, mandating ...
Between 2009 and 2021, nearly 838 pharmacies closed in Illinois, according to researchers at Southern Illinois University in ...
STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...
HYDERABAD: Dr Reddy’s Labs on Wednesday said its subsidiary, Dr Reddy’s Labs SA, has entered into commercialisation and ...
Zacks Investment Research on MSN4d
Here's How to Play JNJ Stock as it Announces $55B US Investment PlanJ&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...
Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...
Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback